Ovid Therapeutics Inc. 8-K

What Happened
Ovid Therapeutics Inc. filed an 8-K reporting that its Series A Warrants (issued in connection with an October 2025 private placement) expired on April 17, 2026. The aggregate number of common shares underlying the Series A Warrants was 38,481,325; investors elected to exercise into 33,597,860 shares of common stock and 4,883,464 pre-funded warrants. The exercises were at $1.40 per common share and $1.399 per pre-funded warrant, producing approximately $53.9 million in gross proceeds. The report was filed April 20, 2026 and signed by Jeffrey Rona, Chief Business and Financial Officer.

Key Details

• Series A Warrants expiration date: April 17, 2026.
• Aggregate underlying shares: 38,481,325.
• Exercise elections: 33,597,860 common shares at $1.40/share; 4,883,464 pre-funded warrants at $1.399/share.
• Gross proceeds to Ovid: approximately $53.9 million.
• Warrants were issued in connection with a private placement in October 2025.

Why It Matters
This event provided Ovid with immediate capital — roughly $53.9M — which can extend the company’s cash runway or fund operations and development programs. At the same time, the company issued 33.6 million new common shares and 4.88 million pre-funded warrants, which increases potential dilution for existing shareholders. Investors should factor the new shares and outstanding pre-funded warrants into assessments of share count and per-share metrics when evaluating Ovid’s financial position.